<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Dublin, Aug. 20, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- The <a href="https://www.researchandmarkets.com/reports/5989564/global-multispecific-antibodies-market-size?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=qvmpbs&amp;utm_campaign=2330887+-+Multispecific+Antibodies+Market+Report+2026%3a+Forecast+to+Reach+%2460+Billion+by+2031%2c+Driven+by+Expanding+Clinical+Pipeline+and+Proprietary+Technologies&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="Global Multispecific Antibodies Market Size, Antibodies Sales, Dosage, Patent, Price, Proprietary Technologies &amp; Clinical Trials Insight 2031">"Global Multispecific Antibodies Market Size, Antibodies Sales, Dosage, Patent, Price, Proprietary Technologies &amp; Clinical Trials Insight 2031"</a> has been added to ResearchAndMarkets.com's offering. The report provides a forward-looking assessment of the global multispecific antibodies market, including commercial performance, clinical development, technology platforms, patents, pricing, dosing, strategic agreements and the competitive landscape. Key Report Findings and Highlights <ul><li>Global multispecific antibodies market opportunity projected to reach USD 60 billion by 2031</li><li>Approximately 40% compound annual growth rate and 430% absolute growth recorded from 2020 to 2025</li><li>Dosage, patent, pricing and sales analysis for approved multispecific antibodies</li><li>Global, regional, annual and quarterly sales data from 2020 through the first quarter of 2026</li><li>Clinical trial analysis by company, therapeutic indication and development phase</li><li>More than 750 multispecific antibodies in clinical trials</li><li>Commercial and clinical insights covering bispecific, trispecific and tetraspecific antibodies</li><li>Competitive analysis of leading pharmaceutical companies and biotechnology developers</li></ul> Multispecific Antibodies Reshape the Therapeutic Market Multispecific antibodies, including bispecific, trispecific and tetraspecific candidates, are becoming an increasingly important component of next-generation drug development. Their capacity to engage multiple biological targets supports therapeutic strategies designed to address tumor heterogeneity, immune evasion and redundant signaling pathways. These characteristics have positioned the category as a major area of investment across oncology, immunology, autoimmune diseases and inflammatory disorders. Momentum generated by approved bispecific antibodies has accelerated research into more advanced multispecific formats. In oncology, developers are increasingly integrating tumor targeting with immune stimulation or immune modulation. This approach is supporting new treatment strategies for difficult-to-treat cancers and patient populations that have exhausted established therapeutic options. The market analysis evaluates the innovation priorities, development barriers and commercial opportunities shaping this rapidly evolving segment. Drawing on a decade of research covering bispecific, trispecific and tetraspecific antibodies, the report examines the potential role of these molecules as key growth drivers for the global antibody therapeutics market. Clinical Trial Pipeline Exceeds 750 Multispecific Antibodies Clinical development remains a decisive factor in determining the commercial outlook for multispecific antibody therapies. Although the number of marketed products remains limited, more than 750 candidates are progressing through clinical studies, with oncology and immunology accounting for substantial pipeline activity. The report reviews early-stage, mid-stage and pivotal clinical trials, with analysis of dosing strategies, safety management, biomarker-based patient selection and regulatory development. Particular attention is given to studies involving relapsed or refractory patient populations, where developers must demonstrate meaningful clinical differentiation from available standards of care. Trials are assessed by indication, development phase, target selection, mechanism, combination strategy, geographic distribution and patient stratification. This analysis helps identify emerging development patterns, competitive areas and factors likely to influence future clinical and regulatory success. Competitive Landscape and Leading Multispecific Antibody Companies The global multispecific antibodies market includes established pharmaceutical companies and specialized biotechnology firms. Roche, Amgen and Johnson &amp; Johnson are applying extensive research, clinical development and commercialization capabilities to advanced antibody programs. Biotechnology companies such as Zymeworks, Alligator Bioscience and ABL Bio are contributing proprietary platforms, differentiated molecular architectures and partnership opportunities. Competition is increasingly influenced by platform quality, manufacturing scalability, molecular stability, safety and target specificity. Amgen continues to advance antibody engineering through its BiTE platform, while QLSF Biotherapeutics has developed the TECAD platform for multispecific molecules incorporating T-cell engagement, co-stimulation and avidity-driven design. Collaborations, Licensing Agreements and Market Consolidation Strategic collaborations, licensing agreements, mergers and acquisitions are accelerating access to proprietary multispecific antibody technologies. Transactions such as the collaboration between Boehringer Ingelheim and Simcere Pharmaceutical Group, along with Genmab's acquisition of Merus in December 2025, illustrate the sector's emphasis on obtaining differentiated platforms, expanding pipelines and sharing development risk. The report analyzes selected partnerships and transactions to assess deal structures, technology priorities and emerging business trends across the multispecific antibodies industry. Market Outlook Through 2031 The outlook for the global multispecific antibodies market remains positive, supported by expanding investment, pipeline progression and continued platform innovation. As more candidates enter advanced clinical development, the potential for additional regulatory approvals and commercial launches is expected to increase. Combination regimens are likely to play a significant role in future market growth, particularly in oncology, where multispecific antibodies are being evaluated as backbone therapies and adjuncts to existing treatments. Development activity is also expanding across autoimmune and inflammatory indications. The report provides pharmaceutical companies, biotechnology developers, investors and other industry stakeholders with an integrated assessment of market size, product sales, pricing, dosage, patents, proprietary technologies, clinical trials and competitive positioning. The findings support informed strategic planning and investment decisions in the global multispecific antibodies market through 2031. Key Topics Covered 1. Research Methodology 2. Introduction to Next Generation Multispecific Antibodies 3. Next Generation Multispecific Antibody Current Clinical Development &amp; Future Commercialization Outlook 3.1 Current Market Overview 3.2 Future Commercialization Opportunity 3.3 Next Generation Multispecific Antibody Proprietary Technologies by Company 4. Next Generation Multispecific Antibody Clinical Trends by Indication 4.1 Cancer 4.2 Hematological Disorders 4.3 Microbial Infections 4.4 Autoimmune &amp; Inflammatory Disorders 4.5 Ocular Diseases 5. Next Generation Multispecific Antibody Clinical Development &amp; Market Trends by Region 5.1 US 5.2 Europe 5.3 China 5.4 UK 5.5 Japan 5.6 Australia 5.7 South Korea 5.8 Canada 6. Approved Multispecific Antibodies - Clinical Overview, Pricing, Dosing &amp; Sales Insight 6.1 Overview 6.2 Clinical Overview, Pricing &amp; Dosage Insight 6.3 Sales Insight (2020 - Q1'2026) 7. Global Multispecific Antibodies Clinical Trials Overview 8. Global Bispecific Antibodies Clinical Trials by Company, Indication &amp; Phase 8.1 Research 8.2 Preclinical 8.3 Phase I 8.4 Phase I/II 8.5 Phase II 8.6 Phase-II/III 8.7 Phase III 8.8 Preregistration 8.9 Registered 9. Marketed Bispecific Antibodies Clinical Insight by Company, Country &amp; Indication 10. Global Trispecific Antibodies Clinical Trials Insight by Company, Country, Indication &amp; Phase 10.1 Research 10.2 Preclinical 10.3 Phase I 10.4 Phase I/II 10.5 Phase II 10.6 Phase II/III 11. Tetraspecific Antibodies Clinical Trials Insight by Company, Country, Indication &amp; Phase 11.1 Preclinical 11.2 Phase I 11.3 Phase I/II 11.4 Phase II 12. Competitive Landscape 12.1 AbbVie 12.2 ABL Bio 12.3 Abzyme Therapeutics 12.4 Affimed Therapeutics 12.5 Akeso Biopharma 12.6 Alligator Bioscience 12.7 Amgen 12.8 APITBIO 12.9 Astellas Pharma 12.10 AstraZeneca 12.11 Aptevo Therapeutics 12.12 BioAtla 12.13 Biocytogen Pharmaceuticals 12.14 Biosion 12.15 CStone Pharmaceuticals 12.16 Diagonal Therapeutics 12.17 EpimAb Biotherapeutics 12.18 FutureGen Biopharmaceutical 12.19 Genentech 12.20 Genmab 12.21 Genor Biopharma 12.22 Gensun Biopharma 12.23 Harbour BioMed 12.24 IGM Biosciences 12.25 I-MAB Biopharma 12.26 ImmuneOnco Biopharma 12.27 ImmunoPrecise Antibodies 12.28 Innate Pharma 12.29 Innovent Biologics 12.30 Invenra 12.31 Johnson &amp; Johnson 12.32 Kenjockety Biotechnology 12.33 LaNova Medicines Limited 12.34 Light Chain Bioscience 12.35 Linton Pharm 12.36 Lyvgen Biopharma 12.37 MacroGenics 12.38 Merck 12.39 Merus 12.40 ModeX Therapeutics (OPKO Health) 12.41 Molecular Partners 12.42 NovaRock Biotherapeutics 12.43 Numab 12.44 OPKO Health 12.45 Pfizer 12.46 Regeneron Pharmaceuticals 12.47 Revitope 12.48 Roche 12.49 Sanofi 12.50 Sichuan Baili Pharmaceutical 12.51 SystImmune 12.52 Virtuoso Therapeutics 12.53 Xencor 12.54 Y-Biologics 12.55 Zymeworks For more information about this report visit <a href="https://www.researchandmarkets.com/reports/5989564/global-multispecific-antibodies-market-size?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=qvmpbs&amp;utm_campaign=2330887+-+Multispecific+Antibodies+Market+Report+2026%3a+Forecast+to+Reach+%2460+Billion+by+2031%2c+Driven+by+Expanding+Clinical+Pipeline+and+Proprietary+Technologies&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/l3iszv</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/MzU0MDI4M2UtNTFhYS00YzkxLWI3NjItMWMxYjlkYjFjMDZlLTEwMjY3MzctMjAyNi0wOC0yMC1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Multispecific Antibodies Market Report 2026: Forecast to Reach $60 Billion by 2031, Driven by Expanding Clinical Pipeline and Proprietary Technologies

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn